Review article: Use of induction therapy in liver transplantation

Transplantation Reviews

Volumn 26, Issue 4, 2012, Pages 246-260

  Rostaing, Lionel ^a   Saliba, Faouzi ^b   Calmus, Yvon ^c   Dharancy, Sébastien ^d   Boillot, Olivier ^e  

^a CHU RANGUEIL   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Alemtuzumab; ATG; Basiliximab; Campath; Induction; Liver transplantation; Simulect; Thymoglobulin

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; DACLIZUMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; APOPTOSIS; B LYMPHOCYTE; CARDIOVASCULAR RISK; CD4+ CD25+ T LYMPHOCYTE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION IMMUNOSUPPRESSIVE THERAPY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER TRANSPLANTATION; LYMPHOCYTE MIGRATION; LYMPHOCYTOPENIA; META ANALYSIS (TOPIC); NEPHROTOXICITY; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; T CELL DEPLETION; TREATMENT DURATION;

EID: 84866775392     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2012.06.002     Document Type: Review

References (80)

1. Uemura T., Schaefer E., Hollenbeak C.S., et al. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. Transpl Int 2011, 24:640-650.
2. Opelz G., Naujokat C., Daniel V., et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006, 81:1227-1233.
3. Webster A.C., Ruster L.P., McGee R., et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010, (1):CD003897.
4. Cosimi A.B., Jenkins R.L., Rohrer R.J., et al. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990, 125:781-784. [discussion 785].
5. Cai J., Terasaki P.I. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation 2010, 90:1511-1515.
6. Moonka D.K., Kim D., Kapke A., et al. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant 2010, 10:590-601.
7. Hanaway M.J., Woodle E.S., Mulgaonkar S., et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011, 364:1909-1919.
8. Mangus R.S., Fridell J.A., Vianna R.M., et al. Immunosuppression induction with rabbit antithymocyte globulin (rATG) ± rituximab in 1000 liver transplants with long-term follow-up. Liver Transpl 2012, Epub ahead of print Jan 12. doi: 10.1002/lt.23381.
9. Préville X., Flacher M., LeMauff B., et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001, 200, 71:460-468.
10. Knechtle S.J., Pirsch J.D., Fechner J.H., et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003, 3:722-730.
11. van der Windt D.J., Smetanka C., Macedo C., et al. Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys. Am J Transplant 2010, 10:773-783.
12. Kovarik J.M., Moore R., Wolf P., et al. Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin Transplant 1999, 13(1 Pt 1):32-38.
13. Tydén G., Genberg H., Tollemar J., et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009, 87:1325-1329.
14. D'Addio F., Yuan X., Habicht A., et al. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation 2010, 90:260-269.
15. Benitez C.E., Puig-Pey I., López M., et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. Am J Transplant 2010, 10:2296-2304.
16. Gurkan S., Luan Y., Dhillon N., et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010, 10:2132-2141.
17. Lopez M., Clarkson M.R., Albin M., et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006, 17:2844-2853.
18. Bloom D.D., Chang Z., Fechner J.H., et al. CD4+ CD25+FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008, 8:793-802.
19. Vondran F.W., Timrott K., Tross J., et al. Impact of basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation. Transpl Int 2010, 23:514-523.
20. Bluestone J.A., Liu W., Yabu J.M., et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008, 8:2086-2096.
21. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005, 80:457-465.
22. Mehrabi A., Mood Zh.A., Sadeghi M., et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant 2007, 22(Suppl. 8):viii54-viii60.
23. Goggins W.C., Pascual M.A., Powelson J.A., et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003, 76:798-802.
24. Bogetti D., Sankary H.N., Jarzembowski T.M., et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant 2005, 19:507-511.
25. Boillot O., Seket B., Dumortier J., et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl 2009, 15:1426-1434.
26. Horton P.J., Tchervenkov J., Barkun J.S., et al. Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients. J Gastrointest Surg 2005, 9:896-902.
27. Tchervenkov J.I., Tzimas G.N., Cantarovich M., et al. The impact of thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant Proc 2004, 36:1747-1752.
28. Jonas S., Rayes N., Neumann U., et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997, 80:1141-1150.
29. Soliman T., Hetz H., Burghuber C., et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007, 13:1039-1044.
30. De Ruvo N., Cucchetti A., Lauro A., et al. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pre-treatment and hepatitis C virus recurrence in liver transplantation. Transplantation 2005, 80:8-12.
31. Tector A.J., Fridell J.A., Mangus R.S., et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004, 10:404-407.
32. Eason J.D., Nair S., Cohen A.J., et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003, 75:1396-1399.
33. Neuhaus P., Clavien P.A., Kittur D., et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002, 8:132-142.
34. Wang X.F., Li J.D., Peng Y., et al. Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials. Transplant Proc 2010, 42:4567-4572.
35. Sato K., Sekiguchi S., Kawagishi N., et al. Unique histopathological features of graft biopsies with liver function abnormalities in living donor liver transplant patients receiving basiliximab induction therapy. Clin Transplant 2011, 25:61-68.
36. Gruttadauria S., Cintorino D., Piazza T., et al. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation. Transplant Proc 2006, 38:1106-1108.
37. Schuller S., Wiederkehr J.C., Coelho-Lemos I.M., et al. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. Transplant Proc 2005, 37:1151-1152.
38. Marcos A., Eghtesad B., Fung J.J., et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004, 78:966-971.
39. Tryphonopoulos P., Madariaga J.R., Kato T., et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc 2005, 37:1203-1204.
40. Tzakis A.G., Tryphonopoulos P., Kato T., et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004, 77:1209-1214.
41. Levitsky J., Thudi K., Ison M.G., et al. Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transpl 2011, 17:32-37.
42. Mihatsch M.J., Kyo M., Morozumi K., et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998, 49:356-363.
43. Nankivell B.J., Borrow R.J., Fung C.L.-S., et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004, 78:557-565.
44. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003, 349:931-940.
45. Paramesh A.S., Roayaie S., Doan Y., et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant 2004, 18:94-99.
46. Cantarovich M., Tchervenkov J., Paraskevas S., et al. Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation 2011, 92:1358-1363.
47. Calmus Y., Kamar N., Gugenheim J., et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. Transplantation 2010, 89:1504-1510.
48. Neuberger J.M., Mamelok R.D., Neuhaus P., et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009, 9:327-336.
49. Yoshida E.M., Marotta P.J., Greig P.D., et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005, 11:1064-1072.
50. Otero A., Varo E., de Urbina J.O., et al. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. Liver Transpl 2009, 15:1542-1552.
51. Klintmalm G.B., Washburn W.K., Rudich S.M., et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007, 13:1521-1531.
52. Lladó L., Xiol X., Figueras J., et al. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study. J Hepatol 2006, 44:710-716.
53. Lladó L., Fabregat J., Castellote J., et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl 2008, 14:1752-1760. THOSIN Study Group.
54. Boillot O., Mayer D.A., Boudjema K., et al. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl 2005, 11:61-67.
55. Filipponi F., Callea F., Salizzoni M., et al. Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004, 78:1488-1495.
56. Pageaux G.P., Calmus Y., Boillot O., et al. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 2004, 10:1454-1460. French CHI-F-01 Study Group.
57. Becker T., Foltys D., Bilbao I., et al. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Transplantation 2008, 86:1689-1694. MARSILEA Study Group.
58. Starzl T.E., Murase N., Abu-Elmagd K., et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003, 361:1502-1510.
59. Masetti M., Montalti R., Rompianesi G., et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010, 10:2252-2262.
60. Charlton M., Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999, 5:S107-S114.
61. Weiler N., Thrun I., Hoppe-Lotichius M., et al. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010, 90:1562-1566.
62. Segev D.L., Sozio S.M., Shin E.J., et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008, 14:512-525.
63. Rosen H.R., Shackleton C.R., Higa L., et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997, 92:1453-1457.
64. Kamar N., Ribes D., Sandres-Saune K., et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. Transplant Proc 2004, 36:2757-2761.
65. Klintmalm G.B., Davis G.L., Teperman L., et al. A randomized multicenter study comparing steroid-free and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011, 17:1394-1403.
66. Kato T., Gaynor J.J., Yoshida H., et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007, 84:829-835.
67. Decaens T., Roudot-Thoraval F., Bresson-Hadni S., et al. Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol 2006, 12:7319-7325.
68. Sharma P., Welch K., Hussain H., et al. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era. Dig Dis Sci 2012, 57:806-812.
69. Liu C.L., Fan S.T., Lo C.M., et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004, 10:728-733.
70. Charpentier B., Rostaing L., Berthoux F., et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003, 75:844-851.
71. Mourad G., Garrigue V., Squifflet J.P., et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001, 72:1050-1055.
72. Soliman T., Hetz H., Burghuber C., et al. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int 2007, 20:447-452.
73. Opelz G., Döhler B. Lymphomas after solid organ transplantation: a Collaborative Transplant Study report. Am J Transplant 2004, 4:222-230.
74. Fernberg P., Edgren G., Adami J., et al. Time trends in risk and risk determinants of non-hodgkin lymphoma in solid organ transplant recipients. Am J Transplant 2011, 11:2472-2482.
75. Herrero J.I., Lorenzo M., Quiroga J., et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005, 11:89-97.
76. Tjon A.S., Sint Nicolaas J., Kwekkeboom J., de Man R.A., et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010, 16:837-846.
77. Guthery S.L., Heubi J.E., Bucuvalas J.C., et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003, 75:987-993.
78. Caillard S., Dharnidharka V., Agodoa L., et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005, 80:1233-1243.
79. van Leeuwen M.T., Grulich A.E., Webster A.C., et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009, 114:630-637.
80. Åberg F., Pukkala E., Höckerstedt K., et al. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl 2008, 14:1428-1436.